Hinge Health (NYSE:HNGE) Sets New 1-Year High - Time to Buy?

Hinge Health Inc. (NYSE:HNGE - Get Free Report) hit a new 52-week high during trading on Monday . The company traded as high as $51.00 and last traded at $49.51, with a volume of 426074 shares traded. The stock had previously closed at $46.51.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Evercore ISI assumed coverage on Hinge Health in a research note on Monday, June 16th. They issued an "outperform" rating and a $50.00 price target for the company. Canaccord Genuity Group initiated coverage on shares of Hinge Health in a report on Monday, June 16th. They issued a "buy" rating and a $52.00 target price on the stock. Truist Financial initiated coverage on shares of Hinge Health in a report on Monday, June 16th. They set a "buy" rating and a $48.00 price target for the company. Royal Bank Of Canada began coverage on shares of Hinge Health in a research note on Monday, June 16th. They issued an "outperform" rating and a $45.00 price objective on the stock. Finally, Bank of America started coverage on Hinge Health in a research note on Monday, June 16th. They set a "buy" rating and a $42.00 target price for the company. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $46.00.

Hinge Health Trading Up 7.9%

Hinge Health Company Profile

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.